| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.80(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.23 - $9.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,011,778 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
766,409 |
1,189,266 |
1,315,394 |
1,951,649 |
| Total Sell Value |
$6,577,948 |
$9,083,370 |
$9,535,666 |
$10,165,404 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
18 |
37 |
59 |
102 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rodriguez Susan |
Chief Commercial Officer |
• – – |
2021-11-22 |
4 |
S |
$0.99 |
$638 |
D/D |
(643) |
197,030 |
|
-19% |
|
| Jacobs Jeffrey W |
Chief Scientific Officer |
• – – |
2021-11-22 |
4 |
AS |
$0.98 |
$5,629 |
D/D |
(5,754) |
119,483 |
|
19% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-11-22 |
4 |
S |
$0.99 |
$182 |
I/I |
(184) |
90,627 |
|
-19% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-11-22 |
4 |
S |
$0.99 |
$638 |
D/D |
(643) |
311,161 |
|
-19% |
|
| Raab Michael |
President & CEO |
• • – |
2021-11-22 |
4 |
S |
$0.99 |
$2,586 |
D/D |
(2,607) |
631,803 |
|
-19% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2021-11-22 |
4 |
S |
$0.99 |
$533 |
D/D |
(537) |
275,958 |
|
-19% |
|
| Jacobs Jeffrey W |
Chief Scientific Officer |
• – – |
2021-11-15 |
4 |
AS |
$1.13 |
$5,650 |
D/D |
(5,000) |
125,237 |
|
-4% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2021-11-12 |
4 |
AS |
$1.13 |
$87,111 |
D/D |
(77,432) |
276,495 |
|
-5% |
|
| Jacobs Jeffrey W |
Chief Scientific Officer |
• – – |
2021-11-08 |
4 |
AS |
$1.18 |
$2,556 |
D/D |
(2,166) |
130,237 |
|
-7% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-10-08 |
4 |
A |
$0.00 |
$0 |
I/I |
60,000 |
90,811 |
|
- |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
311,804 |
|
- |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2021-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
197,673 |
|
- |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2021-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
353,927 |
|
- |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2021-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
294,330 |
|
- |
|
| Blanks Robert |
See Remarks |
• – – |
2021-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
361,511 |
|
- |
|
| Raab Michael |
President & CEO |
• • – |
2021-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
634,410 |
|
- |
|
| Rodriguez Susan |
Chief Commercial Officer |
• – – |
2021-08-20 |
4 |
S |
$1.32 |
$832 |
D/D |
(630) |
44,673 |
|
18% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2021-08-20 |
4 |
S |
$1.32 |
$694 |
D/D |
(526) |
102,386 |
|
18% |
|
| Blanks Robert |
See Remarks |
• – – |
2021-08-20 |
4 |
S |
$1.32 |
$833 |
D/D |
(631) |
106,323 |
|
18% |
|
| Jacobs Jeffrey W |
Chief Scientific Officer |
• – – |
2021-08-20 |
4 |
S |
$1.32 |
$978 |
D/D |
(741) |
127,697 |
|
18% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2021-08-20 |
4 |
S |
$1.32 |
$833 |
D/D |
(631) |
40,047 |
|
18% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-08-20 |
4 |
S |
$1.32 |
$232 |
I/I |
(176) |
26,574 |
|
18% |
|
| Rosenbaum David P. |
Chief Development Officer |
• – – |
2021-08-20 |
4 |
S |
$1.32 |
$833 |
D/D |
(631) |
158,804 |
|
18% |
|
| Raab Michael |
President & CEO |
• • – |
2021-08-20 |
4 |
S |
$1.32 |
$3,396 |
D/D |
(2,573) |
329,730 |
|
18% |
|
| Jacobs Jeffrey W |
Chief Scientific Officer |
• – – |
2021-08-03 |
4 |
D |
$1.64 |
$9,205 |
D/D |
(5,613) |
128,438 |
|
- |
|
538 Records found
|
|
Page 7 of 22 |
|
|
0.29 (3.6%) 
